Apolipoprotein L1 (APOL1) cation current in HEK-293 cells and in human podocytes
Authors:
- 30 November 2022
- journal article
- research article
- Published by Springer Nature in Pflügers Archiv - European Journal of Physiology
- Vol. 475 (3) , 323-341
Abstract
Two heterozygous missense variants (G1 and G2) of Apolipoprotein L1 (APOL1) found in individuals of recent African ancestry can attenuate the severity of infection by some forms of Trypanosoma brucei. However, these two variants within a broader African haplotype also increase the risk of kidney disease in Americans of African descent. Although overexpression of either variant G1 or G2 causes multiple pathogenic changes in cultured cells and transgenic mouse models, the mechanism(s) promoting kidney disease remain unclear. Human serum APOL1 kills trypanosomes through its cation channel activity, and cation channel activity of recombinant APOL1 has been reconstituted in lipid bilayers and proteoliposomes. Although APOL1 overexpression increases whole cell cation currents in HEK-293 cells, the ion channel activity of APOL1 has not been assessed in glomerular podocytes, the major site of APOL1-associated kidney diseases. We characterize APOL1-associated whole cell and on-cell cation currents in HEK-293 T-Rex cells and demonstrate partial inhibition of currents by anti-APOL antibodies. We detect in primary human podocytes a similar cation current inducible by interferon-γ (IFNγ) and sensitive to inhibition by anti-APOL antibody as well as by a fragment of T. brucei Serum Resistance-Associated protein (SRA). CRISPR knockout of APOL1 in human primary podocytes abrogates the IFNγ-induced, antibody-sensitive current. Our novel characterization in HEK-293 cells of heterologous APOL1-associated cation conductance inhibited by anti-APOL antibody and our documentation in primary human glomerular podocytes of endogenous IFNγ-stimulated, APOL1-mediated, SRA and anti-APOL-sensitive ion channel activity together support APOL1-mediated channel activity as a therapeutic target for treatment of APOL1-associated kidney diseases.Keywords
This publication has 58 references indexed in Scilit:
- Pharmacological Inhibitors of Exocytosis and Endocytosis: Novel Bullets for Old Targets2014
- Evolution of the primate trypanolytic factor APOL1Proceedings of the National Academy of Sciences, 2014
- Cell Biology and Pathology of PodocytesAnnual Review of Physiology, 2012
- APOL1 Variants Increase Risk for FSGS and HIVAN but Not IgA NephropathyJournal of the American Society of Nephrology, 2011
- Association of Trypanolytic ApoL1 Variants with Kidney Disease in African AmericansScience, 2010
- Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 geneHuman Genetics, 2010
- Podocytes use FcRn to clear IgG from the glomerular basement membraneProceedings of the National Academy of Sciences, 2008
- Antimuscarinic antibodies in primary Sjögren's syndrome reversibly inhibit the mechanism of fluid secretion by human submandibular salivary acinar cellsArthritis & Rheumatism, 2006
- Trypanosome lytic factor, a subclass of high-density lipoprotein, forms cation-selective pores in membranesMolecular and Biochemical Parasitology, 2005
- Apolipoprotein L-I Promotes Trypanosome Lysis by Forming Pores in Lysosomal MembranesScience, 2005